Vericiguat

Vericiguat: Standard Therapy for HFrEF

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 Patients with heart failure with reduced ejection fraction (HFrEF) continued to experience substantial morbidity and mortality despite contemporary guideline-directed medical therapy (GDMT). The prognosis after worsening heart failure (HF) events remained poor, with approximately 37% 1-year all-cause mortality/HFH rates and 19% 1-year mortality despite optimized medical and device […]

Vericiguat: Standard Therapy for HFrEF Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

GDMT in HFrEF: A Complete Story or a Par al Narrative?

by Prateek Chopra | May 15, 2026 | Cardiology Conferences | ESC-HF 2026 The guideline-directed medical therapy (GDMT) has transformed the prognosis of heart failure with reduced ejec on frac on (HFrEF). The introduc on of the four founda onal pillars, ARNIs or ACE inhibitors, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors, has substan ally reduced mortality and hospitaliza on.

GDMT in HFrEF: A Complete Story or a Par al Narrative? Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation

by Prateek Chopra | May 14, 2026 | Cardiology Conferences | ESC-HF 2026 The session highlighted that heart failure with reduced ejec on frac on (HFrEF) has entered a contemporary treatment era characterized by rapid and comprehensive implementa on of evidence-based therapies. Despite major advances with the four founda onal pillars, ACE inhibitors/ARNIs, beta-blockers, Mineralocor coid receptor antagonists, and SGLT2 inhibitors,

The HFrEF Medica on Toolkit for Pa ents Who Need More: From Evidence to Implementation Read Post »

Leave a Comment / ESC-HF Day 1 / / / , , , ,
Scroll to Top